Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc.CRVS · Entity 4839 | See Remarks | December 04, 2025 | December 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corvus Pharmaceuticals, Inc.
Report date December 04, 2025 · Filed December 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.81 · Expires 2035-12-04 | Direct | 400,000 |
Reported balance
After 2025-12-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-04 · Grant · Acquired 400,000 · Balance 400,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 8, 2025 21:23 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $8.81 | $0.00 |
DisclosureSEC source: 0001610717-25-000412 · form4.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2035-12-04 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:26 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | Exercise / conversionWarrant (Right to Buy) · Derivative | 19,357 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001610717-25-000174 · form4.xml · derivative · entry 2 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,357 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312 per share. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:26 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | Exercise / conversionCommon Stock | 19,357 | $3.50 | $67,749.50 |
DisclosureSEC source: 0001610717-25-000174 · form4.xml · nonDerivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 21:39 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001610717-24-000552 · form4.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-12-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 20, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:06 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseWarrant (Right to Buy) · Derivative | 19,357 | Not disclosed Strike: $3.50 | Not disclosed |
DisclosureSEC source: 0001610717-24-000232 · form4.xml · derivative · entry 2 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,357 Underlying: Common Stock · 19,357 shares Expires 2025-06-30 F1 · price: Issued at no additional consideration to the Reporting Person in connection with their subscription for shares of the Issuer's Common Stock at a price of $1.7312. Read SEC document |
| May 06, 2024 Filed May 7, 2024 21:06 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 20,000 | $1.73 | $34,624.00 |
DisclosureSEC source: 0001610717-24-000232 · form4.xml · nonDerivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,773 Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 21:07 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001610717-23-000392 · form4.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 20, 2022 Filed Dec 20, 2022 23:22 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | PurchaseCommon Stock | 20,000 | $0.79 | $15,800.00 |
DisclosureSEC source: 0001567619-22-021876 · doc1.xml · nonDerivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,773 Read SEC document |
| August 11, 2022 Filed Aug 15, 2022 22:44 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001567619-22-016300 · doc1.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:57 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001567619-21-017013 · doc1.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-09-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from September 9, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:17 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001567619-20-021269 · doc1.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 16, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 12, 2019 Filed Dec 16, 2019 21:12 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001567619-19-023140 · doc1.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2029-12-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 21:09 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0000899243-18-031061 · doc4.xml · derivative · entry 2 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-12-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 21:10 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0000899243-17-028856 · doc4.xml · derivative · entry 2 Jones William Benton · CIK 0001664506 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-12-13 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 13, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 07, 2016 Filed Dec 9, 2016 00:05 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-16-089147 · doc1.xml · derivative · entry 1 Jones William Benton · CIK 0001664506 · VP Pharmaceutical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-forty-eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 7, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.